Skip to main content

Table 1 Relative contribution of HPV 16/18/31/33/45/52/58 in cases of ICC HPV-positive, by region

From: Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

 

World

Africa

Asia

Western/ Central Asia

Eastern Asia

Latin America

South America

Central America

North America

Europe

Oceania

(n = 8,977)

(n = 544)

(n = 2,641)

(n = 836)

(n = 1,805)

(n = 3,404)

(n = 2,629)

(n = 775)

(n = 160)

(n = 2,058)

(n = 170)

 

RC % (95%CI)

RC % (95%CI)

RC % (95%CI)

RC % (95%CI)

RC % (95%CI)

RC % (95%CI)

RC % (95%CI)

RC % (95%CI)

RC % (95%CI)

RC % (95%CI)

RC % (95%CI)

Combinations of HPV types

9 HPV types*

89.4 (88.8-90.1)

86.9 (83.8-89.7)

91.5 (90.4-92.5)

92.0 (89.9-93.7)

91.3 (89.9-92.6)

88.2 (87.0-89.2)

89.2 (87.9-90.3)

84.6 (81.9-87.1)

95.5 (91.2-98.2)

89.1 (87.7-90.4)

89.4 (83.8-93.6)

16/18

70.8 (69.8-71.7)

70.3 (66.2-74.0)

71.6 (69.8-73.4)

77.5 (74.5-80.3)

68.9 (66.7-71.1)

68.2 (66.6-69.8)

69.4 (67.6-71.1)

64.4 (60.9-67.8)

78.8 (71.6-84.8)

72.8 (70.8-74.7)

78.2 (71.3-84.2)

31/33/45/52/58

18.5 (17.7-19.3)

16.7 (13.7-20.1)

19.8 (18.3-21.3)

14.5 (12.2-17.0)

22.3 (20.4-24.3)

19.8 (18.5-21.2)

19.6 (18.1-21.2)

20.3 (17.5-23.3)

16.9 (11.4-23.6)

16.2 (14.6-17.8)

8.8 (5.0-14.1)

Other Types

10.6 (9.9-11.2)

13.0 (10.3-16.2)

8.5 (7.5-9.6)

8.0 (6.3-10.1)

8.7 (7.4-10.1)

11.8 (10.8-13.0)

10.9 (9.7-12.1)

15.4 (12.9-18.1)

4.6 (1.8-8.8)

10.9 (9.6-12.3)

10.6 (6.4-16.2)

Specific HPV types

16

60.5 (59.5-61.6)

47.7 (43.3-51.9)

60.5 (58.6-62.3)

66.7 (63.3-69.8)

57.6 (55.3-59.9)

59.2 (57.5-70.9)

61.3 (59.4-63.2)

52.0 (48.4-55.6)

71.9 (64.2-78.9)

65.5 (63.4-67.6)

58.6 (51.0-66.3)

18

10.3 (9.6-10.9)

22.6 (19.2-26.4)

11.2 (10.0-12.4)

10.8 (8.9-13.2)

11.3 (9.9-12.9)

9.1 (8.1-10.1)

8.1 (7.1-9.2)

12.5 (10.3-15.1)

6.9 (3.48-11.8)

7.3 (6.2-8.5)

19.9 (14.3-26.8)

31

3.7 (3.3-4.1)

1.9 (0.9-3.4)

3.0 (2.4-3.8)

2.8 (1.6-4.0)

3.2 (2.4-4.1)

4.9 (4.2-5.7)

6.5 (5.6-7.6)

4.3 (3.0-5.9)

3.4 (1.0-7.1)

3.4 (2.7-4.3)

0.7 (0.0-3.2)

33

3.8 (3.4-4.3)

1.5 (0.6-2.9)

3.5 (2.8-4.3)

2.5 (1.6-3.8)

4.0 (3.1-4.9)

3.5 (3.2-4.5)

5.0 (4.3-6.0)

2.9 (1.9-4.4)

3.1 (1.0-7.1)

5.7 (4.7-6.8)

2.1 (0.4-5.1)

45

5.9 (5.4-6.4)

9.9 (7.6-12.8)

5.5 (4.7-6.5)

7.0 (5.4-9.0)

4.9 (3.9-6.0)

6.8 (5.9-7.7)

3.7 (3.0-4.4)

7.5 (5.7-9.6)

5.4 (2.6-10.4)

3.9 (3.1-4.8)

5.5 (2.5-9.8)

52

2.8 (2.5-3.2)

2.6 (1.4-4.3)

3.8 (3.1-4.6)

0.8 (0.3-1.7)

5.3 (4.3-6.4)

2.7 (2.2-3.3)

3.0 (2.4-3.7)

1.6 (0.9-2.9)

2.9 (1.0-7.1)

1.9 (1.4-2.6)

0.6 (0.0-3.2)

58

2.3 (2.0-2.6)

0.7 (0.2-1.9)

3.9 (3.2-4.7)

1.3 (0.7-2.3)

5.0 (4.1-6.2)

2.0 (3.3-2.5)

1.4 (1.0-2.0)

3.9 (2.6-5.5)

1.9 (0.39-5.4)

1.3 (0.9-1.9)

0.0 (0.0-2.2)

6

0.1 (0.1-0.2)

0.0 (0.0-0.7)

0.0 (0.0-0.2)

0.0 (0.0-0.4)

0.1 (0.0-0.3)

0.1 (0.0-0.3)

0.1 (0.0-0.3)

0.0 (0.0-0.5)

0.0 (0.0-2.3)

0.2 (0.0-0.4)

1.8 (0.4-5.1)

11

0.0 (0.0-0.1)

0.0 (0.0-0.7)

0.0 (0.0-0.2)

0.0 (0.0-0.4)

0.1 (0.0-0.3)

0.0 (0.0-0.2)

0.0 (0.0-0.2)

0.0 (0.0-0.5)

0.0 (0.0-2.3)

0.0 (0.0-0.2)

0.0 (0.0-2.2)

  1. "ICC": Invasive cervical cancer; “RC”: Relative Contribution; “95%CI”: 95% Confidence Interval; * ”9 HPV types” includes the ones in nine-valent vaccine: HPV 16/18/31/33/45/52/58/6/11.
  2. Additional information: Available data are from unvaccinated women (pre-vaccination period).
  3. Type specific RC estimations: Numerator = single infections + proportional attribution of multiple types; Denominator = HPV DNA positive cervical cancer cases.